TY - JOUR
T1 - Long-term safety and efficacy of intravitreal bevacizumab (avastin) for the management of central retinal vein occlusion
AU - Gregori, Ninel Z.
AU - Gaitan, Jaime
AU - Rosenfeld, Philip J.
AU - Puliafito, Carmen A.
AU - Feuer, William
AU - Flynn, Harry W.
AU - Berrocal, Audina M.
AU - Al-Attar, Luma
AU - Dubovy, Sander
AU - Smiddy, William E.
AU - Schwartz, Stephen G.
AU - Lee, Wen Hsiang
AU - Murray, Timothy G.
PY - 2008/10/1
Y1 - 2008/10/1
N2 - Purpose: To evaluate the long-term safety and efficacy of intravitreal bevacizumab injections (Avastin®, Genentech Inc., San Francisco, CA) for the treatment of macular edema secondary to central retinal vein occlusions. Methods: A retrospective review was performed of eyes treated from May 2005 to August 2006 with follow-up through February 2007. The dose of bevacizumab was 1.25 mg (0.05 mL). Retreatment was performed at monthly or longer intervals at the discretion of the treating physician. Results: Fifty-seven eyes received intravitreal bevacizumab at baseline. Visual acuity improved by a mean of 14 letters (N = 53; P<0.001) at 1 month, 13 letters at 3 months (N = 53; P<0.001), 9 letters at 6 months (N = 30; P = 0.001), 9 letters at 12 months (N = 17; P = 0.004). The mean optical coherence tomography thickness decreased by 299 μm at 1 month (N = 53; P<0.001), 144 μm at 3 months, (N = 53; P<0.001), 127 μm at 6 months (N = 30; P = 0.011), and 276 μm at 12 months (N = 17; P<0.001). No ocular or systemic adverse events were observed. Conclusion: Improvements in visual acuity and optical coherence tomography were observed during the first year following intravitreal bevacizumab for macular edema secondary to central retinal vein occlusions. These retrospective results provide additional evidence to support the perceived safety and efficacy of intravitreal bevacizumab in this disorder. RETINA 28:1325-1337, 2008
AB - Purpose: To evaluate the long-term safety and efficacy of intravitreal bevacizumab injections (Avastin®, Genentech Inc., San Francisco, CA) for the treatment of macular edema secondary to central retinal vein occlusions. Methods: A retrospective review was performed of eyes treated from May 2005 to August 2006 with follow-up through February 2007. The dose of bevacizumab was 1.25 mg (0.05 mL). Retreatment was performed at monthly or longer intervals at the discretion of the treating physician. Results: Fifty-seven eyes received intravitreal bevacizumab at baseline. Visual acuity improved by a mean of 14 letters (N = 53; P<0.001) at 1 month, 13 letters at 3 months (N = 53; P<0.001), 9 letters at 6 months (N = 30; P = 0.001), 9 letters at 12 months (N = 17; P = 0.004). The mean optical coherence tomography thickness decreased by 299 μm at 1 month (N = 53; P<0.001), 144 μm at 3 months, (N = 53; P<0.001), 127 μm at 6 months (N = 30; P = 0.011), and 276 μm at 12 months (N = 17; P<0.001). No ocular or systemic adverse events were observed. Conclusion: Improvements in visual acuity and optical coherence tomography were observed during the first year following intravitreal bevacizumab for macular edema secondary to central retinal vein occlusions. These retrospective results provide additional evidence to support the perceived safety and efficacy of intravitreal bevacizumab in this disorder. RETINA 28:1325-1337, 2008
KW - Avastin
KW - Bevacizumab
KW - Central retinal vein occlusion
KW - Crvo
KW - Intravitreal injection
KW - Macular edema
KW - Vascular endothelial growth factor
KW - Vegf
UR - http://www.scopus.com/inward/record.url?scp=67649230932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649230932&partnerID=8YFLogxK
U2 - 10.1097/IAE.0b013e318188501f
DO - 10.1097/IAE.0b013e318188501f
M3 - Article
C2 - 19430392
AN - SCOPUS:67649230932
VL - 28
SP - 1325
EP - 1337
JO - Retina
JF - Retina
SN - 0275-004X
IS - 9
ER -